Eaton Scientific Systems, Ltd. Announces Plans to Develop a Transdermal Patch Delivery System for Tropine 3 Non-Hormonal Treatment of Hot Flashes
Published: Sep 11, 2012
BEVERLY HILLS, Calif., Sept. 10, 2012 /PRNewswire/ -- Eaton Scientific Systems, Ltd. ("Eaton" or the "Company") a wholly-owned subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased to announce that the Company plans to begin development of a transdermal patch delivery system for Tropine 3, a patent pending novel indication of homatropine for non-hormonal treatment of hot flashes in pre-menopausal, peri-menopausal, and post-menopausal women. The Company believes that this will be the world's first ever available prescription non-hormonal transdermal treatment for hot flash symptoms.
"Tropine 3 is an ideal type of medication to utilize the convenience and dose control accuracy of a transdermal medicated patch delivery system," stated Michael Borkowski, CEO of Eaton Scientific. "Based upon the popular use of Estrogen patches in hormone replacement therapy, it's readily apparent that a high percentage of women could have the same preference when choosing a safe non-hormonal transdermal patch to safely reduce their hot flashes symptoms. We feel this is an opportunity to develop another unique, marketable, and potential patentable feature exclusive to Tropine 3 and Eaton Scientific."
The Company intends to contract with an industry leading drug delivery system expert to assist in the development of the transdermal Tropine 3 patch. Initial testing of various monolithic device transdermal patch technologies and configurations is expected to begin in conjunction with the Company's planned FDA compliant Tropine 3 clinical studies currently being organized to start in the next few weeks.
The transdermal patch was first approved by the U.S. FDA in 1979 as a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. The main advantage of a transdermal drug delivery route is that the patch provides a long-term controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive. Only medications whose molecules are small enough to penetrate the skin can be delivered by transdermal patch. Tropine 3 (homatropine in suspension) molecules are thought to be ideal for transdermal patch delivery.
Further information concerning Tropine 3 development, testing, and marketing will be made in subsequent press releases by the Company.
About Pristine Solutions, Inc.
Pristine Solutions, Inc., through its wholly-owned subsidiary company, Eaton Scientific Systems, Ltd., holds the intellectual property and global marketing rights to Tropine 3, a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, peri-menopausal, and post-menopausal women.
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pristine Solutions' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pristine Solutions' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pristine Solutions herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pristine Solutions disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
SOURCE Eaton Scientific Systems, Ltd.